BeyondSpring Says Lead Asset Posts Positive Data in Phase III NSCLC Trial

BeyondSpring, a New York-China pharma, reported its lead asset, plinabulin, posted positive topline data in a US Phase III trial among NSCLC patients. Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA) that induces antigen presenting cells. It was tested in combination with docetaxel to treat 2nd and 3rd line NSCLC and compared to docetaxel alone. BeyondSpring will file for US approval of plinabulin in NSCLC, its second indication following chemotherapy-induced neutropenia. Decheng has made multiple investments in BeyondSpring. More details.... Stock Symbol: (NSDQ: BYSI) Share this with colleagues: // //